Summit Therapeutics Inc.
SMMT
$18.95
$0.291.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.21B | -1.08B | -921.62M | -746.08M | -240.76M |
| Total Depreciation and Amortization | 165.00K | 146.00K | 126.00K | 104.00K | 87.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 785.95M | 725.09M | 629.43M | 515.59M | 62.43M |
| Change in Net Operating Assets | 35.93M | 31.42M | 22.39M | 23.50M | 5.10M |
| Cash from Operations | -384.05M | -322.93M | -269.67M | -206.88M | -173.14M |
| Capital Expenditure | -480.00K | -657.00K | -507.00K | -494.00K | -557.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -334.18M | -173.65M | 394.84M | 286.28M | -64.55M |
| Cash from Investing | -334.66M | -174.31M | 394.33M | 285.79M | -65.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -24.50M | -100.00M | -100.00M |
| Issuance of Common Stock | 613.65M | 617.53M | 44.60M | 290.43M | 488.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 613.65M | 617.53M | 20.10M | 190.43M | 388.42M |
| Foreign Exchange rate Adjustments | 45.00K | 102.00K | 13.00K | 105.00K | 56.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.01M | 120.40M | 144.78M | 269.44M | 150.23M |